Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877421 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT01877421 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 135 participants.
The verdict
NCT01877421, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.
Interventions
- DRUG 2 mg KSL-W
- DRUG 4 mg KSL-W
- DRUG 6 mg KSL-W
- DRUG 10 mg KSL-W
- DRUG 20 mg KSL-W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2014-02-25 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877421
The ClinicalTrials.gov registry entry for NCT01877421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 2 mg KSL-W is the first listed.
NCT01877421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877421 about?
NCT01877421 is a clinical study titled "Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population". This study is to assess the safety and tolerability of single doses and multiple doses in reducing plaque and gingivitis when delivered in a chewing gum formulation.
What is the current status of trial NCT01877421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2014-02-25. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01877421?
The interventions under investigation include: 2 mg KSL-W (DRUG), 4 mg KSL-W (DRUG), 6 mg KSL-W (DRUG), 10 mg KSL-W (DRUG), 20 mg KSL-W (DRUG).
Who is sponsoring clinical trial NCT01877421?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.